贝伐珠单抗联合FOLFIRI方案对结直肠癌患者Gab2和ZEB1蛋白阳性率的影响  

Effect of Bevacizumab Combined with FOLFIRI Chemotherapy Regimen on the Positive Rate of Gab2 and ZEB1 Protein in Patients with Colorectal Cancer

作　　者：刘宁[1] 杨文浩[1] 王晓宇[2] 钟轩 LIU Ning;YANG Wenhao;WANG Xiaoyu;ZHONG Xuan(Kailuan General Hospital,Hebei,China 063000;Cangzhou Medical College,Guangzhou,Hebei,China 061000;Tangshan Central Hospital,Hebei,China 063000)

机构地区：[1]开滦总医院,河北唐山063000 [2]沧州医学高等专科学校,河北沧州061000 [3]河北省唐山中心医院,河北唐山063000

出　　处：《中国药业》2021年第11期27-30,共4页China Pharmaceuticals

基　　金：河北省医学科学研究课题计划项目[20191341]。

摘　　要：目的探讨贝伐珠单抗联合FOLFIRI方案治疗结直肠癌的疗效,以及对患者Gab2和ZEB1蛋白阳性率的影响。方法选取开滦总医院2017年5月至2019年5月收治的结直肠癌患者98例,按随机数字表法分为观察组和对照组,各49例。两组患者均予FOLFIRI方案治疗,观察组患者加用贝伐珠单抗治疗,2周为1个周期,均连续治疗3个周期。结果观察组患者的客观缓解率、疾病控制率分别为69.39%和79.59%,显著高于对照组的48.98%和61.22%(P<0.05)。治疗后,观察组患者血清肿瘤标志物(癌胚抗原、糖链抗原19-9、糖链抗原50)水平均显著低于对照组(P<0.05);观察组患者Gab2和ZEB1蛋白阳性率分别为36.73%和30.61%,显著低于对照组的59.18%和53.06%(P<0.05);观察组患者血管内皮生长因子、胰岛素样生长因子1、转化生长因子-β1水平均显著低于对照组(P<0.05)。观察组和对照组的不良反应发生率相当(24.49%比16.33%,P>0.05)。结论贝伐珠单抗联合FOLFIRI方案治疗结直肠癌疗效较好,能提高疾病缓解率和疾病控制率,降低肿瘤标志物水平、血清生长因子水平、Gab2和ZEB1蛋白阳性率,且治疗安全性较好。Objective To investigate the efficacy of bevacizumab combined with FOLFIRI chemotherapy regimen in the treatment of patients with colorectal cancer and its effect on the positive rate of Gab2 and ZEB1 protein.Methods A total of 98 patients with colorectal cancer admitted to the Kailuan General Hospital from May 2017 to May 2019 were selected and randomly divided into the observation group and the control group according to the random number table method,49 cases in each group.The patients in the two groups were given FOLFIRI chemotherapy,on this basis,the patients in the observation group were treated with bevacizumab.Both groups were treated for three consecutive cycles with two weeks as a cycle.Results The objective remission rate(ORR)and disease control rate(DCR)of the observation group were 69.39%and 79.59%,which were significantly higher than 48.98%and 61.22%of the control group(P<0.05).After treatment,the levels of serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)and carbohydrate antigen 50(CA50)]in the observation group were significantly lower than those in the control group(P<0.05).The positive rates of Gab2 and ZEB1 protein in the observation group were 36.73%and 30.61%,which were significantly lower than 59.18%and 53.06%in the control group(P<0.05).The levels of vascular endothelial growth factor(VEGF),insulin-like growth factor-1(IGF-1),transforming growth factor-β1(TGF-β1)in the observation group were significantly lower than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was similar to that in the control group(24.49%vs.16.33%,P>0.05).Conclusion Bevacizumab combined with FOLFIRI chemotherapy regimen is effective and safe in the treatment of colorectal cancer,which can improve the ORR and DCR,reduce the level of tumor markers,serum growth factor,and the positive rate of Gab2 and ZEB1 protein.

关 键 词：结直肠癌 贝伐珠单抗 FOLFIRI方案 临床疗效 Gab2蛋白 ZEB1蛋白 肿瘤标志物 血管内皮生长因子 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]